openPR Logo
Press release

Rett Syndrome Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), | DelveInsight | Prilenia Therapeutics, GEXVal, Neurogene Inc, Taysha Gene Therapies, Vyant Bio

07-12-2024 03:24 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Rett Syndrome Market is Predicted to Exhibit Remarkable Growth

The Rett Syndrome Market Forecast report offers an in-depth understanding of the Rett Syndrome, historical and forecasted epidemiology as well as the Rett Syndrome market trends in the 7MM.
DelveInsight's "Rett Syndrome Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Rett Syndrome, historical and forecasted epidemiology as well as the Rett Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Rett Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Rett Syndrome Market Forecast [https://www.delveinsight.com/sample-request/rett-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Rett Syndrome Market Report:

*
The Rett Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In January 2024, Anavex Life Sciences Corp. announced topline results from the Phase II/III EXCELLENCE clinical trial, a randomized, double-blind, placebo-controlled study that assessed the clinical efficacy, safety, and tolerability of 30 mg ANAVEX Registered 2-73 in 92 pediatric patients with Rett syndrome (RTT) aged 5 to 17 years.

*
In March 2023, Melbourne-headquartered Neuren Pharmaceuticals reported that its North American collaborator, Acadia Pharmaceuticals, has obtained approval from the US Food and Drug Administration (FDA) for Neuren's primary candidate, Daybue (trofinetide), designated for addressing Rett syndrome in both adults and children.

*
In February 2023, Unravel Biosciences, Inc., a pharmaceutical firm specializing in developing treatments for intricate diseases through the utilization of a machine-learned model of human health, declared the successful conclusion of its Type B pre-IND meeting with the US Food and Drug Administration (FDA) concerning its RVL001 program targeting Rett Syndrome.

*
In February 2023, PharmaTher Holdings Ltd., a prominent provider of specialized ketamine pharmaceuticals, revealed that the United States Food and Drug Administration (FDA) has granted orphan drug designation to KETARX (racemic ketamine) for addressing Rett Syndrome, a rare genetic neurological condition.

*
As stated by the International Rett Syndrome Foundation (2023), Rett syndrome affects 1 in every 10,000 female births globally and is even rarer in boys. It is typically identified in children between 6 to 18 months when they start missing developmental milestones or lose previously acquired skills.

*
According to the Rett Syndrome Research Trust (2023), approximately 1 in 10,000 girls is born with Rett syndrome. Around 15,000 girls and women in the United States and 350,000 globally are affected by this disorder.

*
Key Rett Syndrome Companies: Prilenia Therapeutics, GEXVal, Neurogene Inc, Taysha Gene Therapies, Vyant Bio, Inc, Neuren Pharmaceuticals, Anavex Life Sciences, PTC Therapeutics, Novartis, Ultragenyx Pharmaceutical, GW Pharmaceuticals, StrideBio, AMO Pharma, Prilenia Therapeutics, Neurolixis, Biohaven Pharmaceuticals, and others

*
Key Rett Syndrome Therapies: Pridopidine, GXV-001, NGN-401, TSHA-102, VYNT-0126, Trofinetide, ANAVEX2-73 (blarcamesine), Vatiquinone, Fingolimod, Triheptanoin, Cannabidivarin, STRX 230, AMO 04, Pridopidine, NLX 101, BHV 5000, and others

*
The Rett Syndrome epidemiology based on gender analzyed that, Rett syndrome occurs more in girls than boys

*
The Rett Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Rett Syndrome pipeline products will significantly revolutionize the Rett Syndrome market dynamics.

Rett Syndrome Overview

Rett Syndrome is a rare genetic neurological disorder that primarily affects girls. It is caused by mutations in the MECP2 gene on the X chromosome. The syndrome typically manifests after 6-18 months of seemingly normal development, followed by a period of rapid regression in motor, cognitive, and social skills.

Get a Free sample for the Rett Syndrome Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/rett-syndrome-market [https://www.delveinsight.com/report-store/rett-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Rett Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Rett Syndrome Epidemiology Segmentation:

The Rett Syndrome market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Rett Syndrome

*
Prevalent Cases of Rett Syndrome by severity

*
Gender-specific Prevalence of Rett Syndrome

*
Diagnosed Cases of Episodic and Chronic Rett Syndrome

Download the report to understand which factors are driving Rett Syndrome epidemiology trends @ Rett Syndrome Epidemiology Forecast [https://www.delveinsight.com/sample-request/rett-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Rett Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Rett Syndrome market or expected to get launched during the study period. The analysis covers Rett Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Rett Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Rett Syndrome Therapies and Key Companies

*
Pridopidine: Prilenia Therapeutics

*
GXV-001: GEXVal

*
NGN-401: Neurogene Inc

*
TSHA-102: Taysha Gene Therapies

*
VYNT-0126: Vyant Bio, Inc

*
Trofinetide: Neuren Pharmaceuticals

*
ANAVEX2-73 (blarcamesine): Anavex Life Sciences

*
Vatiquinone: PTC Therapeutics

*
Fingolimod: Novartis

*
Triheptanoin: Ultragenyx Pharmaceutical

*
Cannabidivarin: GW Pharmaceuticals

*
STRX 230: StrideBio

*
AMO 04: AMO Pharma

*
Pridopidine: Prilenia Therapeutics

*
NLX 101: Neurolixis

*
BHV 5000: Biohaven Pharmaceuticals

Discover more about therapies set to grab major Rett Syndrome market share @ Rett Syndrome Treatment Landscape [https://www.delveinsight.com/sample-request/rett-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Rett Syndrome Market Strengths

*
The use of off-label branded and generic prescription medications targeted at individual symptoms of Rett syndrome, including antiepileptics, antipsychotics, antidepressants and benzodiazepines.

*
Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of Rett syndrome.

Rett Syndrome Market Opportunities

*
New therapeutic options are needed to address the unmet need for effective and curative therapies for Rett syndrome. This has created an opportunity for key players to develop novel therapies targeted towards this indication.

Scope of the Rett Syndrome Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Rett Syndrome Companies: Prilenia Therapeutics, GEXVal, Neurogene Inc, Taysha Gene Therapies, Vyant Bio, Inc, Neuren Pharmaceuticals, Anavex Life Sciences, PTC Therapeutics, Novartis, Ultragenyx Pharmaceutical, GW Pharmaceuticals, StrideBio, AMO Pharma, Prilenia Therapeutics, Neurolixis, Biohaven Pharmaceuticals, and others

*
Key Rett Syndrome Therapies: Pridopidine, GXV-001, NGN-401, TSHA-102, VYNT-0126, Trofinetide, ANAVEX2-73 (blarcamesine), Vatiquinone, Fingolimod, Triheptanoin, Cannabidivarin, STRX 230, AMO 04, Pridopidine, NLX 101, BHV 5000, and others

*
Rett Syndrome Therapeutic Assessment: Rett Syndrome current marketed and Rett Syndrome emerging therapies

*
Rett Syndrome Market Dynamics: Rett Syndrome market drivers and Rett Syndrome market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Rett Syndrome Unmet Needs, KOL's views, Analyst's views, Rett Syndrome Market Access and Reimbursement

To know more about Rett Syndrome companies working in the treatment market, visit @ Rett Syndrome Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/rett-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Rett Syndrome Market Report Introduction

2. Executive Summary for Rett Syndrome

3. SWOT analysis of Rett Syndrome

4. Rett Syndrome Patient Share (%) Overview at a Glance

5. Rett Syndrome Market Overview at a Glance

6. Rett Syndrome Disease Background and Overview

7. Rett Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Rett Syndrome

9. Rett Syndrome Current Treatment and Medical Practices

10. Rett Syndrome Unmet Needs

11. Rett Syndrome Emerging Therapies

12. Rett Syndrome Market Outlook

13. Country-Wise Rett Syndrome Market Analysis (2019-2032)

14. Rett Syndrome Market Access and Reimbursement of Therapies

15. Rett Syndrome Market Drivers

16. Rett Syndrome Market Barriers

17. Rett Syndrome Appendix

18. Rett Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=rett-syndrome-market-is-predicted-to-exhibit-remarkable-growth-during-the-forecast-period-20232032-delveinsight-prilenia-therapeutics-gexval-neurogene-inc-taysha-gene-therapies-vyant-bio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: India
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rett Syndrome Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), | DelveInsight | Prilenia Therapeutics, GEXVal, Neurogene Inc, Taysha Gene Therapies, Vyant Bio here

News-ID: 3579092 • Views:

More Releases from ABNewswire

How to Know When It's Time for an Exterminator: Evo Foam Pest Control's Expert Guide for Austin, TX
How to Know When It's Time for an Exterminator: Evo Foam Pest Control's Expert G …
Not sure when to contact an exterminator? Evo Foam Pest Control explains the common signs of pest problems in Austin and why timely intervention is essential. Austin, TX - Pest infestations can occur at any time, leaving homeowners in Austin, TX, wondering when it's necessary to call an exterminator Austin TX. With numerous pests, including ants, rodents, and termites, threatening the comfort of homes, it's essential to recognize the signs that
Palm Coast Pest Control Shows How Eco-Friendly Pest Control Keeps Jupiter, FL Homes Safe and Healthy
Palm Coast Pest Control Shows How Eco-Friendly Pest Control Keeps Jupiter, FL Ho …
Discover how Palm Coast Pest Control uses eco-friendly solutions to protect Jupiter, FL homes from pests while maintaining a healthy, chemical-free environment. Jupiter, FL - As residents of Jupiter, FL, seek effective and sustainable solutions to pest problems, Palm Coast Pest Control stands out as a trusted provider of eco-friendly pest control services. The company has earned a reputation for its commitment to keeping homes safe, healthy, and pest-free while also
Metro Heat and Air OKC Stands Out for Expertise, Reliability, and Customer Care in Edmond, OK AC Service
Metro Heat and Air OKC Stands Out for Expertise, Reliability, and Customer Care …
Metro Heat and Air OKC is known for delivering top-notch air conditioning services in Edmond, OK, combining professionalism, trustworthiness, and outstanding customer service. Edmond, OK - In Edmond, OK, residents seeking reliable air conditioning services turn to Metro Heat and Air OKC, a trusted HVAC contractor [https://www.google.com/maps?cid=12790181814582558152] committed to delivering exceptional comfort solutions. The company has earned a solid reputation in the area for its high level of expertise, dependability, and
Sugar Rush Lounge at I Dream of Sugar in Nassau, Bahamas Becomes a Destination for Dessert Enthusiasts
Sugar Rush Lounge at I Dream of Sugar in Nassau, Bahamas Becomes a Destination f …
Sugar Rush Lounge in Nassau, Bahamas, delights dessert lovers with unique sweets, making it the go-to spot for indulgence and unforgettable treats. Nassau, Bahamas - The Sugar Rush Lounge is quickly becoming a standout destination in the heart of Nassau, Bahamas. Known for its vibrant energy and inviting atmosphere, this unique dessert-focused lounge blends the indulgence of sweet treats with the stylish ambiance of a Nassau bar and lounge [https://idreamofsugar.com/srl-home/]. Designed

All 5 Releases


More Releases for Rett

Rett Syndrome Market Report 2025-2034: Industry Overview, Trends, And Forecast A …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics. How Big Is the Polymerase Chain Reaction Molecular Diagnostics Market Size Expected to Be by 2034? The market size for polymerase chain reaction molecular diagnostics has significantly expanded in the past few years. The market is projected to rise from $8.97 billion in 2024 to $9.78 billion in 2025, with a compound annual growth
Rett Syndrome Market: Increasing Awareness and Early Diagnosis and Advances in G …
06-06-2024: Maximize Market Research is a Business Consultancy Firm that has published a detailed analysis of the " Rett Syndrome Market". The report includes key business insights, demand analysis, pricing analysis, and competitive landscape. The analysis in the report provides an in-depth aspect at the current status of the Rett Syndrome Market, with forecasts outspreading to the year 2030. Rett Syndrome Market size was valued at USD 350.1
Rett Syndrome Market Industry Outlook, Size, Growth Factors and Forecast 2030
Rett Syndrome Market Insights Unveiled: Embark on a riveting journey through the realms of the Rett Syndrome Market with the cutting-edge market intelligence of a distinguished global research firm. Immerse yourself in a rich tapestry of data and captivating visual representations that decode the enigmatic trends of both regional and global markets. This comprehensive report reveals the market's deepest ambitions, shedding luminous beams on the foremost competitors, their market valuation,
"Understanding Rett Syndrome: Trends and Advances in the Rett Syndrome Market"
The Rett Syndrome Market, valued at USD 225.02 million in 2022, is anticipated to surge to USD 515.06 million by 2029, reflecting a significant Compound Annual Growth Rate (CAGR) of 10.23% from 2023 to 2029. Overview of the Rett Syndrome Market: Rett syndrome, a rare genetic neurological and developmental disorder primarily impacting females, hinders brain development and causes progressive loss of motor skills and language. The market report underscores technological advancements
Europe Rett Syndrome Market Size, Share, Industry, Forecast to 2029
The Europe Rett Syndrome Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Europe Rett Syndrome market. This report explores all the key factors affecting the growth of the global Europe Rett
Rett Syndrome: A Rare Disease Market with Huge Untapped Potential
What is Rett Syndrome? Rett Syndrome is a rare genetic neurological disorder that primarily affects girls. It is caused by a mutation in the MECP2 gene, which is located on the X chromosome. The MECP2 gene provides instructions for making a protein that is critical for the normal development of the brain. Rett Syndrome is a rare disorder, affecting about 1 in every 10,000 to 15,000 live female births. It is a